1, the implementation of quantity procurement has led to a sharp drop in drug prices, and the sales revenue and profit margins of pharmaceutical companies that have not won the bid or negotiated sharply have been severely squeezed.
2. The continuous expansion of the scope of quantity procurement has led to the reduction of vacancies in the generic drug market, the intensification of competitive sales of pharmaceutical companies, and some pharmaceutical companies may face the loss of market share.
3. The reform of medical insurance payment mode has changed from project-based payment to package payment such as disease-based payment and per-head payment, which has led to changes in the income structure and drug use behavior of medical institutions and increased the difficulty of promotion of pharmaceutical companies.
4. Implement the overall management of outpatient service, and bring the designated retail pharmacies into the scope of medical insurance payment, so as to diversify the drug sales channels. Pharmaceutical companies need to adjust their sales strategies and models to adapt to the new market environment.